Search research articles
Contact Us
Filters
Showing results (1-10 of 127) with videos related to
Page
of 13
Sort By:
Hematology Reports
|
October 12, 2020
How I treat relapsed and/or refractory multiple myeloma
Hans C Lee, Claudio Cerchione
Frontiers in Oncology
|
February 22, 2021
Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis
Gregory P Kaufman, Claudio Cerchione
Cell Transplantation
|
September 10, 2020
What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
Sara Bravaccini, Giovanni Martinelli, Claudio Cerchione
Frontiers in Oncology
|
April 12, 2021
Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Claudio Cerchione, Franco Locatelli, Giovanni Martinelli
Recenti Progressi in Medicina
|
July 1, 2023
[Severe Covid-19: to recognize subjects at risk, from the territory to specialist services.]
Claudio Cerchione, Claudio Cricelli, Savina Nodari
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
May 15, 2021
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Claudio Cerchione, Davide Nappi, Giovanni Martinelli
Hematology Reports
|
October 12, 2020
How I manage frontline transplant-eligible multiple myeloma in Italy
Vittorio Montefusco, Giovanni Martinelli, Claudio Cerchione
Methods in Molecular Biology (Clifton, N.J.)
|
March 2, 2021
Urinary Biomarkers in Tumors: An Overview
Ilaria Cimmino, Sara Bravaccini, Claudio Cerchione
Hematology Reports
|
January 7, 2021
The molecular pathogenesis of multiple myeloma
Niccolò Bolli, Giovanni Martinelli, Claudio Cerchione
Frontiers in Oncology
|
May 31, 2024
An overview of prognostic markers in patients with CLL
Julie Braish, Claudio Cerchione, Alessandra Ferrajoli
Page
of 13
Search research articles
Search
Showing results (1-10 of 127) with videos related to
Sort By:
Page
of 13
Hematology Reports
|
October 12, 2020
How I treat relapsed and/or refractory multiple myeloma
Hans C Lee, Claudio Cerchione
Frontiers in Oncology
|
February 22, 2021
Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis
Gregory P Kaufman, Claudio Cerchione
Cell Transplantation
|
September 10, 2020
What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
Sara Bravaccini, Giovanni Martinelli, Claudio Cerchione
Frontiers in Oncology
|
April 12, 2021
Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Claudio Cerchione, Franco Locatelli, Giovanni Martinelli
Recenti Progressi in Medicina
|
July 1, 2023
[Severe Covid-19: to recognize subjects at risk, from the territory to specialist services.]
Claudio Cerchione, Claudio Cricelli, Savina Nodari
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
May 15, 2021
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Claudio Cerchione, Davide Nappi, Giovanni Martinelli
Hematology Reports
|
October 12, 2020
How I manage frontline transplant-eligible multiple myeloma in Italy
Vittorio Montefusco, Giovanni Martinelli, Claudio Cerchione
Methods in Molecular Biology (Clifton, N.J.)
|
March 2, 2021
Urinary Biomarkers in Tumors: An Overview
Ilaria Cimmino, Sara Bravaccini, Claudio Cerchione
Hematology Reports
|
January 7, 2021
The molecular pathogenesis of multiple myeloma
Niccolò Bolli, Giovanni Martinelli, Claudio Cerchione
Frontiers in Oncology
|
May 31, 2024
An overview of prognostic markers in patients with CLL
Julie Braish, Claudio Cerchione, Alessandra Ferrajoli
Page
of 13